Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Carl Zeiss Meditec, Optovue Settle Dispute
Oct 2008
Medical technology company Carl Zeiss Meditec Inc. of Dublin, Calif., and Optovue Corp., a Fremont, Calif.-based maker of optical coherence tomography systems, announced today that they have settled their legal disputes pending in the Northern District of California and in Massachusetts Superior Court, agreeing to licensing and other terms for the disputed intellectual property. Carl Zeiss Meditec, the US-based subsidiary of Carl Zeiss Meditec AG of Jena, Germany, filed a lawsuit in June 2007 in Massachusetts against a former senior sales executive for giving confidential and proprietary company information to his current employer, Optovue. Optovue then filed its own suit against Carl Zeiss Meditec in California. Remaining terms of the settlement agreement are confidential, the companies said.

The technology of generating and harnessing light and other forms of radiant energy whose quantum unit is the photon. The science includes light emission, transmission, deflection, amplification and detection by optical components and instruments, lasers and other light sources, fiber optics, electro-optical instrumentation, related hardware and electronics, and sophisticated systems. The range of applications of photonics extends from energy generation to detection to communications and...
BiophotonicsCarl Zeiss MediteccourtEmploymentintellectual propertylawsuitlicensingNews Briefsoptical coherence tomographyOptovuephotonicsPhotonics Tech Briefsproprietarysettlementsuit

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.